“…As MSCs have been shown to take residence in perivascular space [6,8], they serve as ideal candidates for promotion of the endothelial barrier properties that are necessary to limit cytotoxic damage and influx of immune cells that prime the rejection response. Novel strategies to improve MSC targeting have been discussed in the literature [17,23,35,108,114,122] including hypoxic/pharmacologic preconditioning [122], genetic engineering of MSCs [17], and magnetic-based guidance [23,35,108,114] to focus delivery to the region of interest using systemic delivery after the inciting inflammatory event. Recent work has proposed a new approach that can utilize MSC-based cell therapy to modify the allograft itself at the time of transplantation to facilitate graft tolerance [16,76,78,100,101] (Fig.…”